FT538 in Subjects With Advanced Hematologic Malignancies

General Information

Summary This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Clinical trials phase Phase 1
Start date (estimated) 2020-10-17
End date (estimated) 2038-08-31
Clinical feature
Label acute myeloid leukemia
Link http://purl.obolibrary.org/obo/DOID_9119
Description A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells.; OMIM mapping confirmed by DO. [SN].

Administrative Information

NCT number NCT04614636
ICTRP weblink https://trialsearch.who.int/Trial2.aspx?TrialID=NCT04614636
Other study identifiers
Name FT538-101
Source weblink https://clinicaltrials.gov/ct2/show/NCT04614636
Public contact
Email clinical@fatetherapeutics.com
Public email clinical@fatetherapeutics.com
First name Rebecca
Last name Reynolds
Phone +1 (0)858-875-1800
United States
Sponsors Fate Therapeutics


Which differentiated cell type is used
Label natural killer cell
Link http://purl.obolibrary.org/obo/CL_0000623
Description A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells.


Recruitment Status Recruiting
Estimated number of participants 105